Defiance Daily Target 2X Long NVO ETF

Novo Nordisk Q1 Operating Margin Exceeds Expectations

Novo Nordisk's Experimental Obesity Drug CagriSema Fails Clinical Trial

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

OMER

NVOX

Omeros Corporation's Q1 earnings call highlighted the successful U.S. launch of YARTEMLEA, generating $11.1 million in gross revenue. The company reported a strengthened balance sheet with $135.3 million in cash and a significant deal with Novo Nordisk worth up to $2.1 billion. Despite an adjusted net loss of $17.1 million, management expects YARTEMLEA to drive positive cash flow within 18 months. The stock has declined 38.5% since year-end 2025, raising concerns amid ongoing debt obligations.

Tip Ranks

Omeros

Novo Nordisk AS

Omeros Earnings Call: YARTEMLEA Launch Drives New Phase

HIMS

HIMY

HIMZ

Hims & Hers Health's stock fell over 12% after reporting disappointing Q1 FY2026 results, with an EPS loss of $0.40 and revenue of $608.1 million, missing analyst expectations. This marks the company's fourth consecutive miss on earnings and revenue. Despite the setbacks, the company is optimistic about its GLP-1 strategy with Novo Nordisk and has raised its full-year revenue guidance to $2.8 billion to $3 billion. Analysts maintain a mostly positive outlook, with a consensus Hold rating and potential upside in the stock price.

Market Beat

Hims & Hers Health

Defiance Leveraged Long +Income HIMS ETF

Defiance Daily Target 2X Long HIMS ETF

Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?

LLYX

The FDA has extended its priority review of a subcutaneous formulation of Leqembi for early Alzheimer’s patients, delaying the action date by three months. Analysts are also focusing on upcoming GLP-1 patent expirations, which may impact the drug delivery device market, intensifying competition for injection devices. Additionally, advancements in radiopharmaceuticals are driving growth in oncology, with increased investment and strategic partnerships among major pharmaceutical companies.

Pharmexec

Eli Lilly

SPDR S&P Health Equip

Direxion Daily LLY Bull 2X Shares

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

Defiance Daily Target 2X Long LLY ETF

iShares Biotechnology ETF

iShares US Pharma

VG Health

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

Invesco Nasdaq Biotechnology ETF

iShares US Medical Devices

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

<![CDATA[Pharmaceutical Executive Daily: FDA Extends Review of Leqembi's sBLA]]>

This article discusses whale alerts in the Health Care sector, highlighting significant options trading activity. Notable trades include bearish call options for UNH and HUM, and bullish put options for PFE and NVO. The article details the strike prices, expiration dates, total trade prices, and volumes for each option, indicating potential trading opportunities based on large transactions by influential market players.

benzinga_article

Unitedhealth

Leverage Shares 2X Long UNH Daily ETF

iShares Global Healthcare

iShares US Healthcare Providers

SPDR S&P Health

Pfizer

Humana

4 Health Care Stocks With Whale Alerts In Today's Session

AMZN

The Centers for Medicare & Medicaid Services (CMS) will provide eligible Medicare patients access to Wegovy for obesity treatment at a $50 monthly copay starting July 1, 2026. This initiative, in partnership with Novo Nordisk, aims to expand access to FDA-approved obesity treatments nationwide. The program will cover all Wegovy formulations and is part of the new Medicare GLP-1 Bridge program, allowing patients to work with healthcare professionals for treatment. Additionally, Amazon Pharmacy is expanding access to Novo Nordisk’s oral Ozempic with same-day delivery options.

- The Centers for Medicare & Medicaid Services will provide eligible Medicare beneficiaries with access to Wegovy (semaglutide) for obesity treatment at a $50 monthly copay starting July 1, 2026.  
- This initiative, part of the Medicare GLP-1 Bridge program in partnership with Novo Nordisk A/S, ensures nationwide access to all Wegovy formulations through 2027.  
- The program aims to enhance access to FDA-approved obesity treatments for millions of beneficiaries, allowing them to collaborate with healthcare professionals for treatment.

Amazon

Direxion Daily AMZN Bull 2X Shares

AST SpaceMobile

Rakuten Group, Inc.

CMS To Offer Wegovy To Eligible Medicare Patients At $50 Monthly Copay Starting July 2026

The global point-of-care diagnostics market has reached $58.76 billion in 2026, growing nearly 10% annually. Digital health startups attracted $4 billion in Q1 2026, with a focus on delivering clinical-grade results through innovative channels. VentriPoint Diagnostics is set to showcase its AI-powered cardiac imaging platform at a major cardiology conference in Italy. The company is expanding its regulatory approvals and commercial partnerships, including a collaboration with Hims & Hers Health and Novo Nordisk to enhance access to FDA-approved medications. Analysts project the market will reach $114.65 billion by 2035, driven by technological advancements.

PR Newswire

Mannkind

Ginkgo Bioworks

GINKGO BIOWORKS HOLDINGS INC C/WTS 16/09/2026 (TO PUR COM)

The $59B Quiet Shift Reshaping How Patients Access Care

Novo Nordisk Q1 sales DKK70.1bn (-10% YoY); adjusted operating profit down 15%. Obesity drug Wegovy sales rose; Ozempic sales hit two-year low amid competition including Eli Lilly’s Foundayo.1Novo Nordisk rolls out Wegovy in 50+ countries as supply improves, expanding global availability to meet demand; rivals like Eli Lilly are also pursuing international launches.2Novo Nordisk (NOVO_B) GLP‑1 Wegovy now available via Amazon One Medical. Pricing: $25/month with insurance, $149/month cash. Offered through One Medical primary care for eligible patients.3

TradingView

SPDR S&P Retail ETF

VanEck Retail ETF

Roundhill AMZN WeeklyPay ETF

GraniteShares 2x Long AMZN Daily ETF

Amplify Online Retail ETF

Global X E-commerce ETF

ProShares Online Retail

Key facts: Novo Nordisk Q1 sales down; Wegovy 50+ countries, Amazon

Novo Nordisk partners with Hims & Hers to sell FDA-approved GLP-1 drugs to eligible customers, including Wegovy (injectable and oral) and Ozempic pens; expands retail access to these meds.1Novo Nordisk: once‑weekly semaglutide 2.4 mg cut MACE in SELECT perimenopausal women ~42% vs placebo and ~13% in postmenopausal women; subgroup difference not statistically significant.2

Key facts: Novo Nordisk sells GLP‑1s via Hims & Hers;MACE down 42%/13%

Eli Lilly (LLY) has invested an additional $4.5 billion in its Indiana manufacturing facilities, raising its total investment to over $21 billion since 2020. This funding supports the development of advanced gene therapies and its new obesity pill, Foundayo, which has seen strong initial demand. The investment also aims to enhance production capabilities for retatrutide, targeting obesity and cardiometabolic diseases. Analysts maintain a Strong Buy consensus on Eli Lilly's shares, with a price target suggesting a 28% upside.

Eli Lilly (LLY) Raises Bet to $21B as Obesity Pill War with Novo Nordisk Intensifies

QURE

VKTX

Today's whale activity in health care stocks reveals significant trading opportunities. Notable options include bullish call sweeps for HIMS, NVO, VKTX, and ELV, with varying expiration dates and strike prices. REPL shows a bullish put trade, while QURE has a bearish call trade. The data indicates abnormal trading volumes, suggesting potential market movements. Traders are advised to monitor these activities closely for investment strategies.

Defiance Daily Target 2X Long NVO ETF(NVOX.US)